Lakefront Biotherapeutics NV current report, Q2 FY2022

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of June 2022. The filing, dated June 23, 2022, incorporates by reference a press release issued on June 20, 2022 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. Note: The input metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The provided filing text does not contain specific financial data. It serves as a cover document to incorporate a press release by reference. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.

Material Changes

The filing text does not disclose specific material changes to financial position or operations. It indicates that a material event or announcement was made via the attached press release (Exhibit 99.1), but the content of that announcement is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, guidance, outlook, or specific risk factors. It states that the information in the attached press release is incorporated into the Company's Registration Statements on Forms F-3 and S-8.

Investor Verification Checklist

  • Verify the content of Exhibit 99.1 (Press Release dated June 20, 2022) to understand the specific material event triggering this filing.
  • Confirm the registrant identity is Galapagos NV and not Lakefront Biotherapeutics NV, as the filing text explicitly names Galapagos.
  • Review the referenced Registration Statements (Forms F-3 and S-8) for updated disclosures related to the press release.
  • Check subsequent filings for financial metrics if the press release pertained to a financial update or transaction.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.